LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,214
تعداد مقالات11,073
تعداد مشاهده مقاله75,494,182
تعداد دریافت فایل اصل مقاله100,381,462
Nazari-Vanani, Razieh, Sattarahmady, Naghmeh, Karimian, Khashayar, Heli, Hossein. (1404). An in Vitro Study on Anticancer Efficacy of Capecitabine- and Vorinostat-incorporated Self-nanoemulsions. سامانه مدیریت نشریات علمی, 15(4), 353-368. doi: 10.31661/jbpe.v0i0.2405-1757
Razieh Nazari-Vanani; Naghmeh Sattarahmady; Khashayar Karimian; Hossein Heli. "An in Vitro Study on Anticancer Efficacy of Capecitabine- and Vorinostat-incorporated Self-nanoemulsions". سامانه مدیریت نشریات علمی, 15, 4, 1404, 353-368. doi: 10.31661/jbpe.v0i0.2405-1757
Nazari-Vanani, Razieh, Sattarahmady, Naghmeh, Karimian, Khashayar, Heli, Hossein. (1404). 'An in Vitro Study on Anticancer Efficacy of Capecitabine- and Vorinostat-incorporated Self-nanoemulsions', سامانه مدیریت نشریات علمی, 15(4), pp. 353-368. doi: 10.31661/jbpe.v0i0.2405-1757
Nazari-Vanani, Razieh, Sattarahmady, Naghmeh, Karimian, Khashayar, Heli, Hossein. An in Vitro Study on Anticancer Efficacy of Capecitabine- and Vorinostat-incorporated Self-nanoemulsions. سامانه مدیریت نشریات علمی, 1404; 15(4): 353-368. doi: 10.31661/jbpe.v0i0.2405-1757

An in Vitro Study on Anticancer Efficacy of Capecitabine- and Vorinostat-incorporated Self-nanoemulsions

Journal of Biomedical Physics and Engineering
مقاله 6، دوره 15، شماره 4 - شماره پیاپی 1، آبان 2025، صفحه 353-368    اصل مقاله (2.48 M)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.2405-1757
نویسندگان
Razieh Nazari-Vanani1؛ Naghmeh Sattarahmady1، 2؛ Khashayar Karimian3؛ Hossein Heli* 1
1Nanomedicine and Nanobiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Arasto Pharmaceutical Chemicals Inc., Yousefabad, Jahanarar Avenue, Tehran, Iran
چکیده
Background: Cancer has emerged as a critical global health concern due to its widespread prevalence and impact on individuals, families, communities, and healthcare systems worldwide.
Objective: We investigated the anticancer effectiveness of capecitabine (CAP) and vorinostat (VOR) when incorporated into self-nanoemulsifying drug delivery systems (SNEDDSs).
Material and Methods: In this experimental study, the SNEDDSs were formulated using polyethylene glycol 600 (PEG 600), castor oil and Tween 80. A ternary phase diagram was plotted for the SNEDDSs components and the single-phase formation region was attained. SNEDDSs were then prepared by dilution of the selected ratios of these components in water. Blank SNEDDSs containing ratios (in weight) of castor oil:Tween 80:PEG 600 of 50:30:20 (S1-SNEDDS) and 25:15:60 (S2-SNEDDS) were selected. S1-SNEDDS was loaded with CAP (S1-SNEDDS-CAP), and S2-SNEDDS was loaded with VOR (S2-SNEDDS-VOR).
Results: The developed SNEDDSs formed oil nanodroplets without phase separation. Using dynamic laser light scattering, S1-SNEDDS, S2-SNEDDS, S1-SNEDDS-CAP and S2-SNEDDS-VOR had droplets with average sizes of 171±37, 82±18, 117±26 and 37±8 nm, respectively, accompanied by span values of 0.96, 0.95, 0.97 and 0.96, respectively. CAP and VOR were effectively loaded into the SNEDDSs with high entrapment efficiencies and loading capacities. Considerable improvements in cells viability for CAP and VOR were attained upon loading into SNEDDSs. TUNEL assays of the cells upon treatment by S1-SNEDDS-CAP and S2-SNEDDS-VOR revealed a significant apoptosis in all the cells. 
Conclusion: The study provides valuable insights into the potential of utilizing SNEDDSs as a novel delivery system for improving the anticancer properties of CAP and VOR.

تازه های تحقیق

Hossein Heli (Google Scholar)

 

کلیدواژه‌ها
Zolinza؛ 5-Deoxy-5-Fluorouridine؛ Deacetylase Inhibitor؛ Nanoemulsion؛ Anticancer Efficacy؛ Drug Delivery Systems؛ Phase Separation؛ MCF7 Cells؛ PANC1 Cells؛ Hela Cell Lines
مراجع
  1. Ali I, Rahis-Uddin, Salim K, Rather MA, Wani WA, Haque A. Advances in nano drugs for cancer chemotherapy. Curr Cancer Drug Targets. 2011;11(2):135-46. doi: 10.2174/156800911794328493. PubMed PMID: 21158724.
  2. Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem. 2006;6(6):513-23. doi: 10.2174/187152006778699121. PubMed PMID: 17100556.
  3. De La Cruz L, Blankenship SA, Chatterjee A, Geha R, Nocera N, Czerniecki BJ, et al. Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. Ann Surg Oncol. 2016;23(10):3247-58. doi: 10.1245/s10434-016-5313-1. PubMed PMID: 27357177.
  4. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18(6):1337-45. doi: 10.1200/JCO.2000.18.6.1337. PubMed PMID: 10715306.
  5. Vainchtein LD, Rosing H, Schellens JH, Beijnen JH. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5’-deoxy-5-fluorocytidine, 5’-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma. Biomed Chromatogr. 2010;24(4):374-86. doi: 10.1002/bmc.1302. PubMed PMID: 19650151.
  6. Devanaboyina N, Kishore YS, Pushpalatha P, Mamatha N, Venkatesh P. Development and validation of new RP HPLC method for analysis of capecitabine in pharmaceutical dosage form. Int J Sci Invent Today. 2013;2(1):21-30.
  7. Sun SB, Liu P, Shao FM, Miao QL. Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer. Int J Clin Exp Med. 2015;8(10):19670-81. PubMed PMID: 26770631. PubMed PMCID: PMC4694531.
  8. Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, et al The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013;23(5):341-8. doi: 10.1097/CMR.0b013e328364c0ed. PubMed PMID: 23963286. PubMed PMCID: PMC4012016.
  9. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269(1):7-17. doi: 10.1016/j.canlet.2008.03.037. PubMed PMID: 18462867.
  10. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012;90(1):85-94. doi: 10.1038/icb.2011.100. PubMed PMID: 22124371.
  11. Chidambaram M, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci. 2011;14(1):67-77. doi: 10.18433/j30c7d. PubMed PMID: 21501554.
  12. Ajdari M, Ranjbar A, Karimian K, Karimi M, Heli H, Sattarahmady N. Characterization and Evaluation of Nano-niosomes Encapsulating Docetaxel against Human Breast, Pancreatic, and Pulmonary Adenocarcinoma Cancer Cell Lines. J Biomed Phys Eng. 2024;14(2):159-68. doi: 10.31661/jbpe.v0i0.2401-1708. PubMed PMID: 38628892. PubMed PMCID: PMC11016824.
  13. Nazari-Vanani R, Sattarahmady N, Heli H. Nanotechnological approaches for enhancing the oral bioavailability of curcumin. J Biol Today’s World. 2017;6(7):129-32. doi: 10.15412/J.JBTW.01060702.
  14. Denis I, El Bahhaj F, Collette F, Delatouche R, Gueugnon F, Pouliquen D, et al. Vorinostat-polymer conjugate nanoparticles for Acid-responsive delivery and passive tumor targeting. 2014;15(12):4534-43. doi: 10.1021/bm501338r. PubMed PMID: 25333409.
  15. Negahdary M, Behjati-Ardakani M, Sattarahmady N, Yadegari H, Heli H. Electrochemical aptasensing of human cardiac troponin I based on an array of gold nanodumbbells-Applied to early detection of myocardial infarction. Sens Actuators B Chem. 2017;252:62-71. doi: 10.1016/j.snb.2017.05.149.
  16. Ajdari MR, Tondro GH, Sattarahmady N, Parsa A, Heli H. Phytosynthesis of silver nanoparticles using Myrtus communis L. leaf extract and investigation of bactericidal activity. J Electron Mat. 2017;46:6930-5. doi: 10.1007/s11664-017-5784-2.
  17. Dehdari Vais R, Yadegari H, Heli H, Sattarahmady N. A β-Amyloid(1-42) Biosensor Based on Molecularly Imprinted Poly-Pyrrole for Early Diagnosis of Alzheimer’s Disease. J Biomed Phys Eng. 2021;11(2):215-28. doi: 10.31661/jbpe.v0i0.1070. PubMed PMID: 33937128. PubMed PMCID: PMC8064131.
  18. Dehdari Vais R, Yadegari H, Heli H. Synthesis of Flower-like Nickel Hydroxide Nanosheets and Application in Electrochemical Determination of Famotidine. Iran J Pharm Res. 2020;19(1):120-37. doi: 10.22037/ijpr.2019.14257.12245. PubMed PMID: 32922475. PubMed PMCID: PMC7462516.
  19. Negahdary M, Heli H. An electrochemical peptide-based biosensor for the Alzheimer biomarker amyloid-β(1-42) using a microporous gold nanostructure. Mikrochim Acta. 2019;186(12):766. doi: 10.1007/s00604-019-3903-x. PubMed PMID: 31713687.
  20. Negahdary M, Heli H. An electrochemical troponin I peptisensor using a triangular icicle-like gold nanostructure. Biochem Eng J. 2019;151:107326. doi: 10.1016/j.bej.2019.107326.
  21. Karimi M, Karimian K, Heli H. A nanoemulsion-based delivery system for imatinib and in vitro anticancer efficacy. Braz J Pharm Sci. 2021;56:e18973. doi: 10.1590/s2175-97902020000118973.
  22. Wang J, Li B, Qiu L, Qiao X, Yang H. Dendrimer-based drug delivery systems: history, challenges, and latest developments. J Biol Eng. 2022;16(1):18. doi: 10.1186/s13036-022-00298-5. PubMed PMID: 35879774. PubMed PMCID: PMC9317453.
  23. Papagiannaros A, Bories C, Demetzos C, Loiseau PM. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed Pharmacother. 2005;59(10):545-50. doi: 10.1016/j.biopha.2005.06.011. PubMed PMID: 16325367.
  24. Nazari-Vanani R, Kayani Z, Karimian K, Ajdari MR, Heli H. Development of New Nanoniosome Carriers for Vorinostat: Evaluation of Anticancer Efficacy In Vitro. J Pharm Sci. 2024;113(8):2584-94. doi: 10.1016/j.xphs.2024.05.025. PubMed PMID: 38801974.
  25. Liu M, Du H, Zhai G. The Design of Amphiphilic Polymeric Micelles of Curcumin for Cancer Management. Curr Med Chem. 2015;22(38):4398-411. doi: 10.2174/092986732238151228191020. PubMed PMID: 26714503.
  26. Nasr A, Gardouh A, Ghorab M. Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation. 2016;8(3):20. doi: 10.3390/pharmaceutics8030020. PubMed PMID: 27355963. PubMed PMCID: PMC5039439.
  27. Köllner S, Nardin I, Markt R, Griesser J, Prüfert F, Bernkop-Schnürch A. Self-emulsifying drug delivery systems: Design of a novel vaginal delivery system for curcumin. Eur J Pharm Biopharm. 2017;115:268-75. doi: 10.1016/j.ejpb.2017.03.012. PubMed PMID: 28323109.
  28. Qian J, Meng H, Xin L, Xia M, Shen H, Li G, Xie Y. Self-nanoemulsifying drug delivery systems of myricetin: Formulation development, characterization, and in vitro and in vivo evaluation. Colloids Surf B Biointerfaces. 2017;160:101-9. doi: 10.1016/j.colsurfb.2017.09.020. PubMed PMID: 28917148.
  29. Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martínez Leal JF, De La Cueva P, et al. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. 2010;95(4):613-21. doi: 10.3324/haematol.2009.013870. PubMed PMID: 20133897. PubMed PMCID: PMC2857191.
  30. Huang C, Ida H, Ito K, Zhang H, Ito Y. Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol. 2007;73(7):990-1000. doi: 10.1016/j.bcp.2006.12.013. PubMed PMID: 17276407.
  31. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, et al. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. 2011;226(9):2378-90. doi: 10.1002/jcp.22574. PubMed PMID: 21660961.
  32. Wilson-Edell KA, Yevtushenko MA, Rothschild DE, Rogers AN, Benz CC. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Res Treat. 2014;144(2):287-98. doi: 10.1007/s10549-014-2877-y. PubMed PMID: 24562770. PubMed PMCID: PMC4318538.
  33. Kwak TW, Kim DH, Jeong YI, Kang DH. Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells. J Nanobiotechnology. 2015;13:60. doi: 10.1186/s12951-015-0122-4. PubMed PMID: 26410576. PubMed PMCID: PMC4583727.
  34. Han L, Wang T, Wu J, Yin X, Fang H, Zhang N. A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy. Int J Nanomedicine. 2016;11:6003-22. doi: 10.2147/IJN.S118727. PubMed PMID: 27956831. PubMed PMCID: PMC5113930.
  35. Tran TH, Ramasamy T, Truong DH, Shin BS, Choi HG, Yong CS, Kim JO. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res. 2014;31(8):1978-88. doi: 10.1007/s11095-014-1300-z. PubMed PMID: 24562809.
  36. Kjellström J, Kjellén E, Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol. 2005;44(7):687-93. doi: 10.1080/02841860500247552. PubMed PMID: 16227158.
  37. Yuan F, Shi H, Ji J, Cai Q, Chen X, Yu Y, et al. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis. Oncol Rep. 2015;33(4):1753-62. doi: 10.3892/or.2015.3765. PubMed PMID: 25634241.
  38. Mohammadian M, Zeynali S, Azarbaijani AF, Khadem Ansari MH, Kheradmand F. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res Pharm Sci. 2017;12(6):517-25. doi: 10.4103/1735-5362.217432. PubMed PMID: 29204180. PubMed PMCID: PMC5691578.
  39. Payghan SA. Nanoengineered erythrovesicles: camouflaged capecitabine as a biomimetic delivery platform. Asian J Pharm. 2017;11(1):53-63. doi: 10.22377/ajp.v11i01.1044.
  40. Zou F, Wei K, Peng X. Thermodynamics of micellization and sustained release of folate targeted capecitabine loaded nanomicelles. J Nanosci Nanotechnol. 2016;16(8):8519-27. doi: 10.1166/jnn.2016.12710.
  41. Wei K, Peng X, Zou F. Folate-decorated PEG-PLGA nanoparticles with silica shells for capecitabine controlled and targeted delivery. Int J Pharm. 2014;464(1-2):225-33. doi: 10.1016/j.ijpharm.2013.12.047. PubMed PMID: 24463073.
  42. Kwak TW, Lee HL, Song YH, Kim C, Kim J, Seo SJ, et al. Vorinostat-eluting poly(DL-lactide-co-glycolide) nanofiber-coated stent for inhibition of cholangiocarcinoma cells. Int J Nanomedicine. 2017;12:7669-80. doi: 10.2147/IJN.S141920. PubMed PMID: 29089762. PubMed PMCID: PMC5655133.
  43. Akbari R, Javar HA. Efficacy of capecitabine and 5-fluorouracil (5-FU) on the human breast cancer cell line (MCF7)–effect of concentration. Am J Res Commun. 2013;1(16):75-91.
  44. Tran TH, Choi JY, Ramasamy T, Truong DH, Nguyen CN, Choi HG, et al. Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polym. 2014;114:407-15. doi: 10.1016/j.carbpol.2014.08.026. PubMed PMID: 25263908.
  45. Ziegler DS, Kung AL. Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol. 2008;20(1):97-103. doi: 10.1097/CCO.0b013e3282f310f6. PubMed PMID: 18043263.
  46. Rebello S, Asok AK, Mundayoor S, Jisha MS. Surfactants: toxicity, remediation and green surfactants. Environ Chem Lett. 2014;12(2):275-87. doi: 10.1007/s10311-014-0466-2.
  47. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2007;66(2):227-43. doi: 10.1016/j.ejpb.2006.10.014. PubMed PMID: 17127045.
  48. Fracasso PM, Goldstein LJ, De Alwis DP, Rader JS, Arquette MA, Goodner SA, et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res. 2004;10(21):7220-8. doi: 10.1158/1078-0432.CCR-04-0452. PubMed PMID: 15534095.
  49. Sohail MF, Rehman M, Sarwar HS, Naveed S, Salman O, Bukhari NI, et al. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine. 2018;13:3145-61. doi: 10.2147/IJN.S164518. PubMed PMID: 29922053. PubMed PMCID: PMC5997133.
  50. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-47. doi: 10.1016/s0169-409x(02)00228-4. PubMed PMID: 12628320.
  51. Li M, Zhang N, Li M. Capecitabine treatment of HCT-15 colon cancer cells induces apoptosis via mitochondrial pathway. Trop J Pharm Res. 2017;16(7):1529-36. doi: 10.4314/tjpr.v16i7.10. Anticancer Efficacy; Drug Delivery Systems; Phase Separation; MCF7 Cells; PANC1 Cells; Hela Cell Lines
  52.  
آمار
تعداد مشاهده مقاله: 134,790
تعداد دریافت فایل اصل مقاله: 445


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب